Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 9/13/26 | Akeso (9926) | Idafang for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/9/26 | Tyra Biosciences (TYRA) | TYRA-300 for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/8/26 | Inhibrx (INBX) | INBRX-106 for Head and Neck Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/8/26 | Structure (GPCR) | aleniglipron for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/8/26 | Bristol Myers Squibb (BMY) | Arlo-cel for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 09/30/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Trial Completion |
| 10/28/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 10/31/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/11/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/13/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |